biote Corp.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
BTMD$1.11+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $24,123 | $39,342 |
| Accounts receivable, net | 6,868 | 7,631 |
| Inventory, net | 19,064 | 14,845 |
| Other current assets | 4,615 | 6,309 |
| Total current assets | 54,670 | 68,127 |
| Property and equipment, net | 10,753 | 6,973 |
| Capitalized software, net | 4,525 | 3,877 |
| Goodwill | 5,833 | 5,833 |
| Intangible assets, net | 4,266 | 5,500 |
| Operating lease right-of-use assets | 2,701 | 3,246 |
| Deferred tax assets, net | 24,793 | 28,742 |
| Other non-current assets | 72 | 72 |
| Total assets | $107,613 | $122,370 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $6,826 | $5,813 |
| Accrued expenses | 9,806 | 11,293 |
| Term loan, current | 6,250 | 6,250 |
| Deferred revenue, current | 3,017 | 2,961 |
| Earnout liabilities, current | — | 100 |
| Operating lease liabilities, current | 592 | 523 |
| Share repurchase liabilities, current | 18,500 | 24,574 |
| Total current liabilities | 44,991 | 51,514 |
| Term loan, net of current portion | 95,782 | 101,199 |
| Revolving loans | 5,000 | — |
| Deferred revenue, net of current portion | 1,097 | 1,553 |
| Operating lease liabilities, net of current portion | 2,298 | 2,890 |
| Share repurchase liabilities, net of current portion | — | 44,300 |
| Other non-current liability | 344 | 1,500 |
| TRA liability | 4,386 | 4,479 |
| Earnout liabilities, net of current portion | 4,112 | 17,135 |
| Total liabilities | 158,010 | 224,570 |
| Commitments and contingencies (See Note 19) | ||
| Stockholders’ Deficit | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2025 and 2024, respectively | — | — |
| Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 32,300,867 and 33,073,277, shares issued, 30,713,367 and 31,485,777 shares outstanding as of December 31, 2025 and 2024, respectively | 3 | 3 |
| Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 7,249,879 shares issued, 5,221,653 shares outstanding each as of December 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | — | — |
| Accumulated deficit | (49,549) | (100,297) |
| Accumulated other comprehensive loss | (29) | (35) |
| Treasury stock, at cost | (8,965) | (5,600) |
| biote Corp.’s stockholders’ deficit | (58,539) | (105,928) |
| Noncontrolling interest | 8,142 | 3,728 |
| Total stockholders’ deficit | (50,397) | (102,200) |
| Total liabilities and stockholders’ deficit | $107,613 | $122,370 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.